What Drugs Are to Reviewed by Fda This Month

• With pediatric COVID-nineteen cases surpassing x million and at the asking of the FDA, the companies take submitted available data on the safety and efficacy of ii 3 µg doses as role of a three-dose principal series for this age group to address the urgent public health need
• Companies plan to submit boosted information on a third 3 µg dose in this age group in the coming months
• If authority is granted, the Pfizer-BioNTech vaccine would exist the first COVID-xix vaccine available for pediatric populations nether 5 years of age

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that following a asking from the U.S. Food and Drug Assistants (FDA) the companies have initiated a rolling submission seeking to amend the Emergency Use Potency (EUA) of the Pfizer-BioNTech COVID-xix Vaccine to include children 6 months through 4 years of age (6 months to <5 years of age), in response to the urgent public health need in this population. The companies await to complete the EUA submission in the coming days. This application is for dominance of the first two 3 µg doses of a planned iii-dose main series in this age grouping. Data on a 3rd dose given at least 8 weeks after completion of the 2d dose are expected in the coming months and will be submitted to the FDA to support a potential expansion of this requested EUA.

Since the pandemic began, more than than x.six 1000000 children have tested positive for COVID-19 in the U.Due south.,¹ with children under 4 accounting for more than than 1.6 million of those cases.² Further, reported COVID-19 cases and related hospitalization among children accept spiked dramatically beyond the Usa during the Omicron variant surge. For the week catastrophe Jan 22, children under 4 deemed for 3.2% of the total hospitalizations due to COVID-19.^two If authority is granted, the Pfizer-BioNTech COVID-19 Vaccine would exist the first vaccine available to assist protect children nether 5 years of age from this disease, potentially including future emerging variants of concern.

"As hospitalizations of children under 5 due to COVID-19 accept soared, our mutual goal with the FDA is to gear up for future variant surges and provide parents with an selection to help protect their children from this virus," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "Ultimately, we believe that 3 doses of the vaccine will be needed for children vi months through 4 years of age to achieve high levels of protection against current and potential hereafter variants. If 2 doses are authorized, parents will take the opportunity to begin a COVID-19 vaccination series for their children while awaiting potential authorization of a third dose."

"Our vaccine has already demonstrated a favorable safety, tolerability and efficacy profile in multiple clinical trials and existent-world studies for all historic period groups starting from five years old," said Ugur Sahin, Chiliad.D., CEO and Co-founder of BioNTech. "If authorized, we are very excited most the prospect of offering parents the opportunity to help protect their children vi months through 4 years of historic period from COVID-nineteen and the potentially severe consequences of infection."

The request to amend the EUA is based on the totality of data on the safety, tolerability, immunogenicity, and available efficacy of two doses of the Pfizer-BioNTech COVID-19 Vaccine. The companies also program to share these data with the European Medicines Agency and other regulatory agencies effectually the world.

The companies program to provide ample supply of the 3 µg dose to meet demand should the FDA approve the EUA application. The companies previously announced planned global supply chapters of approximately iv billion doses of the Pfizer-BioNTech COVID-19 Vaccine in 2022. The companies continue to supply the vaccine under their existing supply agreement with the U.S. government, which continues through Apr 2022.

About the Phase one/ii/3 Trial in Children

The Phase i/ii/3 trial initially enrolled 4,500 children ages 6 months to nether 12 years of age in the United States, Finland, Poland, and Spain from more than xc clinical trial sites. Additional children take been enrolled in all historic period groups following study amendments and the trial currently includes approximately 8,300 children. It was designed to evaluate the condom, tolerability, and immunogenicity of the Pfizer-BioNTech vaccine on a two-dose schedule (approximately 21 days apart) in three age groups: ages 5 to under 12 years; ages 2 to under 5 years; and ages 6 months to nether 2 years. Based on the Phase 1 dose-escalation portion of the trial, children ages five to nether 12 years received a two-dose schedule of x µg each while children nether age 5 received a lower three µg dose for each injection in the Phase 2/three written report. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection. On December 17, 2021, Pfizer and BioNTech announced the companies would exam a third 3 µg dose given at least two months after the second dose in children under age v and a third dose of the 10 µg formulation in children v to under 12 years of age.

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech's proprietary mRNA applied science, was developed past both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency utilize authorizations or equivalents in the Usa (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency apply authorizations or equivalent were initially granted are planned.

U.S. Indication & Authorized Employ

HOW IS THE VACCINE GIVEN?

The vaccine will be given as an injection into the muscle.

Primary Series:
In individuals 5 years of historic period and older, the vaccine is administered as a ii-dose series, 3 weeks apart. In individuals v years of age and older, a third primary series dose may be administered at least 28 days later on the second dose to individuals who are determined to accept certain kinds of immunocompromise.

Booster Dose:

• A unmarried booster dose of the vaccine may be administered at to the lowest degree 5 months after completion of a primary series of the Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY^® (COVID-xix Vaccine, mRNA) to individuals 12 years of age and older
• A single booster dose of the vaccine may exist administered to individuals 18 years of age and older who have completed primary vaccination with a unlike authorized COVID-nineteen vaccine. Individuals should check with their healthcare provider regarding timing of the booster dose

WHAT IS THE INDICATION AND AUTHORIZED Utilize?

The Pfizer-BioNTech COVID-xix Vaccine has received EUA from FDA to provide:

• a ii-dose master series to individuals 5 years of historic period and older
• a third primary series dose to individuals five years of age and older who have been determined to accept certain kinds of immunocompromise
• a single booster dose to individuals 12 years of age and older who have completed a chief series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY^® (COVID-xix Vaccine, mRNA)
• a unmarried booster dose to individuals 18 years of historic period and older who take completed primary vaccination with a different authorized COVID-19 vaccine. The booster schedule is based on the labeling information of the vaccine used for the primary series

COMIRNATY^® (COVID-19 Vaccine, mRNA) is an FDA-canonical COVID-xix vaccine made by Pfizer for BioNTech.

• It is approved as a ii-dose series for prevention of COVID-19 in individuals 16 years of age and older
• Information technology is also authorized under EUA to provide:
  • a two-dose master series to individuals 12 through 15 years of historic period
  • a 3rd main serial dose to individuals 12 years of age and older who have been adamant to take certain kinds of immunocompromise
  • a single booster dose to individuals 12 years of historic period and older who have completed a main series with Pfizer-BioNTech COVID-xix Vaccine or COMIRNATY^® (COVID-19 Vaccine, mRNA)
  • a single booster dose to individuals 18 years of age and older who have completed main vaccination with a different authorized COVID-19 vaccine. The booster schedule is based on the labeling data of the vaccine used for the chief series

EUA Statement

Emergency uses of the vaccine have non been approved or licensed by FDA, but take been authorized past FDA, under an Emergency Use Say-so (EUA) to prevent Coronavirus Illness 2019 (COVID-19) in individuals 5 years of age and older. The emergency uses are only authorized for the elapsing of the declaration that circumstances exist justifying the authority of emergency utilise of the medical production under Section 564(b)(1) of the FD&C Human action unless the proclamation is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-u.s.a..com.

Of import SAFETY INFORMATION

Individuals should not go the vaccine if they:

• had a severe allergic reaction after a previous dose of this vaccine
• had a severe allergic reaction to whatever ingredient of this vaccine

Individuals should tell the vaccination provider about all of their medical atmospheric condition, including if they:

• accept whatever allergies
• have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the center)
• take a fever
• have a haemorrhage disorder or are on a blood thinner
• are immunocompromised or are on a medicine that affects the immune organization
• are pregnant, plan to go meaning, or are breastfeeding
• have received another COVID-19 vaccine
• accept e'er fainted in association with an injection

The vaccine may non protect everyone.

Side effects reported with the vaccine include:

• There is a remote chance that the vaccine could cause a severe allergic reaction
  • A severe allergic reaction would usually occur inside a few minutes to 1 hour afterward getting a dose of the vaccine. For this reason, vaccination providers may inquire individuals to stay at the place where they received the vaccine for monitoring after vaccination
  • Signs of a severe allergic reaction can include difficulty animate, swelling of the confront and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness
  • If an individual experiences a severe allergic reaction, they should call 9-1-ane or become to the nearest hospital
• Myocarditis (inflammation of the centre musculus) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine, more unremarkably in males under forty years of historic period than amongst females and older males. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The adventure of having this occur is very depression. Individuals should seek medical attention right away if they have any of the following symptoms afterwards receiving the vaccine:
  • chest pain
  • shortness of breath
  • feelings of having a fast-beating, fluttering, or pounding centre
• Additional side furnishings that have been reported with the vaccine include:
  • severe allergic reactions; non-severe allergic reactions such equally rash, itching, hives, or swelling of the confront; myocarditis (inflammation of the centre muscle); pericarditis (inflammation of the lining outside the heart); injection site hurting; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); decreased appetite;diarrhea; vomiting; arm hurting; fainting in association with injection of the vaccine
• These may not be all the possible side effects of the vaccine. Serious and unexpected side furnishings may occur. The possible side effects of the vaccine are still existence studied in clinical trials. Call the vaccination provider or healthcare provider almost bothersome side effects or side effects that do not go away

Data on assistants of this vaccine at the same time every bit other vaccines take not yet been submitted to FDA. Individuals considering receiving this vaccine with other vaccines, should talk over their options with their healthcare provider.

Patients should always ask their healthcare providers for medical communication about agin events. Individuals are encouraged to report negative side effects of vaccines to the Us Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit https://world wide web.vaers.hhs.gov or call one‐800‐822‐7967. In addition, side effects tin be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.

Click for

Fact Sheets and Prescribing Data for individuals 12 years of age and older

Full Prescribing Data (sixteen years of age and older) DILUTE Before Use, Royal Cap
Total Prescribing Information (16 years of age and older) DO NOT DILUTE, Grayness Cap
EUA Fact Sheet for Vaccination Providers (12 years of age and older), Royal Cap
EUA Fact Sheet for Vaccination Providers (12 years of age and older), Gray Cap
Recipients and Caregivers Fact Canvass (12 years of age and older)

Fact Sheets for individuals 5 through 11 years of age

EUA Fact Sheet for Vaccination Providers (5 through 11 years of age), Orangish Cap
Recipients and Caregivers Fact Canvas (5 through 11 years of historic period)

About Pfizer: Breakthroughs That Modify Patients' Lives

At Pfizer, nosotros apply scientific discipline and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to ready the standard for quality, safety and value in the discovery, evolution and industry of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues piece of work beyond developed and emerging markets to advance wellness, prevention, treatments and cures that claiming the most feared diseases of our fourth dimension. Consistent with our responsibility as one of the earth'south premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the globe. For more than 170 years, we have worked to brand a difference for all who rely on us. We routinely post information that may be important to investors on our website at world wide web.Pfizer.com. In addition, to learn more, please visit the states on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and similar us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice

The information independent in this release is every bit of February one, 2022. Pfizer assumes no obligation to update forward-looking statements contained in this release as the consequence of new information or future events or developments.

This release contains forward-looking information virtually Pfizer's efforts to gainsay COVID-xix, the collaboration between BioNTech and Pfizer to develop a COVID-xix vaccine, the BNT162b2 mRNA vaccine program, and the Pfizer-BioNTech COVID-19 Vaccine, also known as COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a rolling submission to request an amendment to the emergency employ authorization to include children 6 months through four years of age in the U.Southward. and plans to share these data with the European Medicines Agency and other regulatory agencies, a potential third dose in children half-dozen months through iv years of age, BNT162b2'southward potential against time to come emerging variants of concern, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of data readouts, regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause bodily results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in enquiry and development, including the ability to meet anticipated clinical endpoints, start and/or completion dates for clinical trials, regulatory submission dates, regulatory approving dates and/or launch dates, likewise as risks associated with preclinical and clinical information (including the Stage 1/2/iii of Phase 4 information) for BNT162b2 or any other vaccine candidate in the BNT162 programme in any of our studies in pediatrics, adolescents or adults or existent world evidence, including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or rubber data or further information regarding the quality of pre-clinical, clinical or safety information, including by audit or inspection; the power to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Stage three trial and additional studies, in real-earth information studies or in larger, more various populations following commercialization; the power of BNT162b2 or whatsoever time to come vaccine to preclude COVID-19 acquired by emerging virus variants; the take a chance that more than widespread use of the vaccine will lead to new information most efficacy, condom, or other developments, including the take a chance of additional adverse reactions, some of which may be serious; the chance that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine programme will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities volition be satisfied with the pattern of and results from these and whatever future preclinical and clinical studies; whether and when submissions to asking emergency utilise or conditional marketing authorizations for BNT162b2 in boosted populations, for a potential booster dose for BNT162b2 or any potential future vaccines (including potential future almanac boosters or re-vaccination), and/or other biologics license and/or emergency use authorisation applications or amendments to whatsoever such applications may be filed in detail jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 plan, including a potential variant-based vaccine, and if obtained, whether or when such emergency use authorizations or licenses volition elapse or terminate; whether and when whatever applications that may be pending or filed for BNT162b2 (including the requested amendment to the EUA in the U.S. to include children 6 months through 4 years of age or whatever other requested amendments to emergency utilize or provisional marketing authorizations) or other vaccines that may result from the BNT162 plan may exist canonical by particular regulatory authorities, which volition depend on myriad factors, including making a conclusion equally to whether the vaccine's benefits outweigh its known risks and determination of the vaccine's efficacy and, if approved, whether it will be commercially successful; decisions by regulatory government impacting labeling or marketing, manufacturing processes, safe and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between united states and our collaboration partners, clinical trial sites or third-political party suppliers; the chance that demand for any products may exist reduced or no longer be; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine's formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not exist able to successfully develop other vaccine formulations, booster doses or potential future almanac boosters or re-vaccinations or new variant-based vaccines; the hazard that we may not exist able to maintain or scale up manufacturing capacity on a timely footing or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements volition be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the bear upon of COVID-19 on Pfizer'southward business, operations and fiscal results; and competitive developments.

A further clarification of risks and uncertainties can be found in Pfizer'southward Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Take chances Factors" and "Forwards-Looking Information and Factors That May Impact Future Results", equally well as in its subsequent reports on Grade viii-K, all of which are filed with the U.South. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About BioNTech

Biopharmaceutical New Technologies is a adjacent generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech Forward-looking Statements

This press release contains "forward-looking statements" of BioNTech within the meaning of the Private Securities Litigation Reform Human action of 1995. These forwards-looking statements may include, just may not be express to, statements apropos: BioNTech's efforts to combat COVID-xix; the collaboration between BioNTech and Pfizer including the program to develop a COVID-nineteen vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a rolling submission to amend the Emergency Use Authority to include children vi months through 4 years of age in the U.S., the potential of a third dose in children half-dozen months through 4 years of age, qualitative assessments of available information, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial utilize based on data observations to date; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase iii trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to preclude COVID-xix caused by emerging virus variants; the expected time point for boosted readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; preclinical and clinical trial data that are discipline to differing interpretations and assessments, including during the peer review/publication procedure, in the scientific community generally, and by regulatory authorities; the widespread employ of our vaccine that may lead to new information about efficacy, rubber, or other developments, including the take chances of boosted adverse reactions, some of which may exist serious; the timing of submissions to request emergency apply or provisional marketing authorizations for a potential booster dose, pediatric populations and/or other biologics license and/or emergency use potency applications or amendments to whatever such applications may be filed in particular jurisdictions for BNT162b2 or whatever other potential vaccines that may arise from the BNT162 program, including a potential variant-based vaccine, and if obtained, whether or when such emergency utilise authorizations or licenses will expire or terminate; decisions past regulatory regime that may bear upon labeling or marketing, manufacturing processes, rubber and/or other matters that could impact the availability or commercial potential of our vaccine, including development of products or therapies past other companies; the timing for submission of information for, or receipt of, any marketing approval or emergency employ authorization, which will depend on myriad factors, including making a determination every bit to whether the vaccine'southward benefits outweigh its known risks and decision of the vaccine'south efficacy and, if approved, whether it will be commercially successful; our contemplated aircraft and storage plan, including our estimated production shelf life at various temperatures; disruptions in the relationships betwixt us and our collaboration partners, clinical trial sites or other 3rd-parties; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine's conception, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling later on delivery by BioNTech and third-political party providers; the ability of BioNTech to supply the quantities of BNT162 to support clinical evolution and market place need, including our production estimates for 2021; whether and when boosted supply agreements will be reached; challenges related to public vaccine confidence or awareness; and uncertainties regarding the impact of COVID-xix to BioNTech's trials, business organization and general operations. Any forrad-looking statements in this press release are based on BioNTech electric current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those gear up forth in or unsaid by such forward-looking statements. These risks and uncertainties include, simply are not limited to: the ability to meet the pre-divers endpoints in clinical trials; contest to create a vaccine for COVID-19; the power to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability contour observed to date, in the remainder of the trial or in larger, more various populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

For a word of these and other risks and uncertainties, see BioNTech'due south Annual Report as Course xx-F for the Year Concluded December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC's website at world wide web.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by constabulary.

_____________________________
¹ Children and COVID-19: State-Level Data Report. American Academy of Pediatrics. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-country-level-information-report/. Updated January xx, 2022. Accessed January 28, 2022.
ⁱⁱ Laboratory-Confirmed COVID-19-Associated Hospitalizations. Centers for Affliction Control and Prevention. https://gis.cdc.gov/grasp/covidnet/covid19_5.html. Updated January 22, 2022. Accessed Jan 28, 2022.

Source: Pfizer Inc.

egbertwilen1995.blogspot.com

Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency

Share this post